The Board of Directors comment on the outcome of the rights issue
After several questions have been received, the Board of Cline Scientific AB (“Cline” or “The Company”) has the following initial comment on the outcome of the Company's rights issue which was communicated in a press release yesterday, November 30, 2022."After the Company's rights issue has been closed and the outcome compiled, we want to start by thanking our shareholders for their continued trust. Our assessment is that it is still difficult for R&D companies to raise capital and based on this we are satisfied with the outcome. We made a strategic decision to keep the discount for the